BRAF and melanoma: Although significant advances have been made in the development of new therapies for melanoma, especially in targeted and immunotherapy such as BRAF/MEK inhibitors and checkpoint inhibitor blockade therapies [2], more than half of patients with advanced melanoma succumb to the disease.